Myrcene

Myrcene is an acyclic monoterpene that exerts anti-inflammatory effects by inhibiting COX-2 at 71% and COX-1 at 25% at 0.54 mg/mL in vitro, and produces sedative and analgesic activity through reduction of locomotor activity in rodent models at 100–200 mg/kg. Preclinical data further show it reduces HeLa cervical cancer cell viability by approximately 40% at 10–100 nM concentrations while displaying relative selectivity against non-transformed fibroblasts, positioning it as a promising but clinically unvalidated multi-target bioactive monoterpene.

Origin & History

Myrcene (β-myrcene, C₁₀H₁₆) is an acyclic monoterpene occurring naturally in cannabis (Cannabis sativa), hops (Humulus lupulus), mangoes (Mangifera indica), lemongrass (Cymbopogon citratus), thyme (Thymus vulgaris), and bay laurel (Laurus nobilis). It is biosynthesized via the mevalonate pathway from geranyl pyrophosphate and accumulates predominantly in glandular trichomes of cannabis and lupulin glands of hops. Industrial isolation occurs primarily through steam distillation or solvent extraction from these botanical sources, with cannabis-derived myrcene commanding premium interest due to co-occurring synergistic phytocannabinoids and terpenes.

Historical & Cultural Context

Myrcene has been consumed indirectly by humans for millennia through hops-bittered beer, with Humulus lupulus documented in European brewing records dating to the 9th century CE and myrcene contributing to the characteristic herbal, musky aroma and mild sedative quality of hopped ales. In traditional Mesoamerican and South Asian ethnobotany, mango (Mangifera indica) preparations were used for digestive complaints and as mild relaxants, with myrcene now identified as a contributor to these effects. Cannabis preparations rich in myrcene-dominant chemotypes have been employed in Ayurvedic, Islamic, and Chinese traditional medicine systems for analgesic, sedative, and anti-inflammatory purposes, with the 'indica' effect profile in modern cannabis culture frequently attributed in part to high myrcene concentrations exceeding 0.5% by weight. Lemongrass and thyme, both myrcene-containing herbs, appear extensively in traditional European and Asian herbal pharmacopoeias for antimicrobial, carminative, and anti-spasmodic indications, providing further historical context for myrcene's bioactivity.

Health Benefits

- **Anti-inflammatory Activity**: Myrcene inhibits COX-2 enzyme activity by 71% and COX-1 by 25% at 0.54 mg/mL in vitro, suppressing prostaglandin synthesis and downstream inflammatory cascades comparable to early-stage pharmaceutical COX inhibitors.
- **Sedative and Anxiolytic Effects**: At 100–200 mg/kg in rodent open-field tests, myrcene significantly reduces crossing, rearing, and grouping behaviors, suggesting central nervous system depressant activity potentially mediated via GABAergic or adenosine receptor pathways.
- **Analgesic Properties**: Animal studies indicate myrcene potentiates opioid-mediated antinociception and reduces pain responses independently, likely through modulation of descending pain pathways and interaction with peripheral nociceptors.
- **Potential Anticancer Effects**: In vitro MTT assays demonstrate ~40% reduction in HeLa cervical cancer cell viability at 10–100 nM myrcene, with comparatively milder cytotoxicity (~20–30% at 10–500 nM) against non-transformed human dermal fibroblasts (HDFa), suggesting a degree of tumor-cell selectivity.
- **Antioxidant Activity**: Myrcene scavenges reactive oxygen species and free radicals through electron donation from its conjugated diene system, contributing to reduced lipid peroxidation in cellular models.
- **Antimutagenic Effects**: Preclinical data indicate myrcene inhibits mutagenesis induced by cyclophosphamide and other genotoxic agents in Salmonella-based Ames assays, suggesting DNA-protective potential at the cellular level.
- **Transdermal Penetration Enhancement**: At 0.3–1.2% w/w in topical formulations, myrcene disrupts stratum corneum lipid packing, enhancing dermal absorption of co-administered active compounds and offering utility as a natural permeation enhancer.

How It Works

Myrcene exerts anti-inflammatory effects primarily through competitive inhibition of cyclooxygenase enzymes, achieving 71% COX-2 and 25% COX-1 inhibition at 0.54 mg/mL in vitro, thereby reducing arachidonic acid conversion to pro-inflammatory prostaglandins and thromboxanes. Its sedative and anxiolytic properties are attributed to modulation of GABAergic neurotransmission and possible agonism at adenosine A2A receptors, with open-field behavioral data in rodents corroborating central nervous system depression at 100–200 mg/kg doses. Anticancer activity proceeds through induction of cytotoxic pathways in transformed cells, with HeLa cell viability reductions of ~40% at 10–100 nM suggesting interference with mitotic progression or apoptotic signaling, though the precise molecular target—whether tubulin polymerization, caspase activation, or reactive oxygen species generation—remains under investigation. The compound's lipophilic acyclic diene structure (log P ≈ 4.3) facilitates rapid membrane permeation, yielding peak plasma concentrations of 14.1±3.0 μg/mL at 60 minutes post 1 g/kg oral administration in rats and detectable human plasma levels within 30 minutes of ingestion.

Scientific Research

The evidence base for myrcene consists entirely of in vitro cell studies and animal pharmacology experiments; no published randomized controlled trials or controlled human clinical studies with defined sample sizes and effect sizes have been identified as of this writing. Key preclinical findings include HeLa cell cytotoxicity (~40% viability reduction at 10–100 nM by MTT assay), rodent locomotor suppression at 100–200 mg/kg in open-field testing, COX-1/COX-2 inhibition quantified at 0.54 mg/mL in enzyme assays, and rat oral pharmacokinetic profiling showing peak plasma at 14.1±3.0 μg/mL after 1 g/kg dosing. Antimutagenic activity has been documented in bacterial mutagenicity assays, and antinociceptive effects have been reported in hot-plate and writhing rodent models. The translation of these findings to human therapeutic outcomes is highly uncertain, and the absence of Phase I/II clinical trial data means that effective human doses, safety thresholds, and clinical efficacy endpoints remain formally unestablished.

Clinical Summary

No human clinical trials investigating myrcene as an isolated therapeutic agent have been published with sufficient methodological detail to yield generalizable effect sizes or confidence intervals. Available preclinical data from rodent and in vitro models demonstrate pharmacological activity across anti-inflammatory, sedative, analgesic, and cytotoxic domains, but species-to-human dose translation is complicated by the high mg/kg doses required in animals. Pharmacokinetic studies in rats confirm adequate oral bioavailability with detectable plasma peaks at 60 minutes, and human inhalation or ingestion of myrcene-containing botanicals (cannabis, hops, mangoes) provides indirect exposure data, though isolate-specific human trials are absent. Confidence in myrcene's clinical efficacy for any indication must therefore be rated as low-to-preliminary, warranting well-designed Phase I safety and Phase II efficacy trials before clinical recommendations can be made.

Nutritional Profile

β-Myrcene (C₁₀H₁₆, MW 136.23 g/mol) is a monoterpene hydrocarbon, not a macronutrient or micronutrient source. It contains no vitamins, minerals, fiber, or protein. It is a volatile lipophilic bioactive compound found at concentrations of 0.1–0.5% (w/w) in hops (Humulus lupulus), 0.5–3.0% in lemongrass (Cymbopogon citratus) essential oil, up to 40–65% of Cannabis sativa essential oil profiles, and 1–20% in mango (Mangifera indica) fruit flesh volatiles. As a highly lipophilic terpene (logP ~4.17), oral bioavailability is moderate and enhanced significantly by co-administration with lipid carriers or phospholipid complexes. Myrcene undergoes rapid first-pass hepatic metabolism via CYP2B enzymes, yielding hydroxylated metabolites including myrcene-10-ol and myrcene-1,2-diol. Plasma half-life in rodent models is approximately 1–2 hours. Typical bioactive dosing ranges studied in preclinical models are 25–200 mg/kg body weight orally.

Preparation & Dosage

- **Dietary Supplement Capsules/Softgels**: Proposed therapeutic range of 10–50 mg/day; no clinically validated human dose exists; lipid-based softgels (MCT oil base) preferred to enhance absorption given water insolubility.
- **Tinctures (Oral)**: Formulated at 0.2–0.8% w/w in MCT or hemp seed oil carriers; nitrogen-flushed amber glass bottles recommended to prevent oxidative degradation; typical serving 1–2 mL per dose.
- **Vaporization/Inhalation**: Concentration range 0.8–1.2% in vape formulations; boiling point 166–168°C means low-temperature vaporization (160–170°C) preserves compound integrity; most commonly encountered as a component of whole-plant cannabis terpene profiles.
- **Topical Preparations**: 0.3–1.2% w/w in cream or balm bases; at these concentrations myrcene also functions as a dermal penetration enhancer for co-formulated actives; patch or transdermal delivery systems under investigation.
- **Beverages and Edibles**: 0.01–0.08% w/w or 5–20 ppm; nanoemulsion technology (droplet size <200 nm) significantly improves aqueous retention and bioavailability given inherent water insolubility.
- **Essential Oil (Aromatherapy)**: Diffused at low concentrations (1–3 drops per 100 mL water); inhalation route yields rapid plasma appearance within 30 minutes; sedative applications typically employ evening diffusion protocols.
- **Standardization Note**: No pharmacopeial standardization established; cannabis-derived myrcene should specify β-myrcene purity ≥92% by GC-MS; botanical-derived isolates may contain α-myrcene and other monoterpene impurities.

Synergy & Pairings

β-Myrcene pairs synergistically with **linalool** (found in lavender, 200–400 mg doses), as both modulate GABAergic neurotransmission—myrcene potentiates GABA_A receptor activity while linalool acts as a positive allosteric modulator, producing enhanced sedative and anxiolytic effects beyond either compound alone. **Limonene** (from citrus peel, 100–300 mg) complements myrcene's anti-inflammatory COX-2 inhibition by independently suppressing NF-κB signaling and IL-6 production, broadening the anti-inflammatory cascade coverage. **β-Caryophyllene** (from black pepper/clove, 50–200 mg) acts as a selective CB2 cannabinoid receptor agonist, and when combined with myrcene's ability to increase cell membrane permeability and enhance transdermal/mucosal absorption of co-administered compounds, the pair delivers amplified analgesic and anti-inflammatory outcomes. Additionally, **curcumin** (150–500 mg, with piperine for bioavailability) synergizes with myrcene on overlapping COX-2 and prostaglandin E₂ suppression pathways, providing multi-target anti-inflammatory activity.

Safety & Interactions

At low supplemental doses (10–50 mg/day), myrcene is generally considered safe in healthy adults, with reported adverse effects limited to dose-dependent drowsiness, dry mouth, and mild gastrointestinal discomfort including nausea at higher intakes; rodent acute oral tolerance studies demonstrate survival and tolerability at 1 g/kg, suggesting a wide safety margin relative to proposed human doses. Sedative effects are pharmacodynamically additive with cannabinoids (particularly at cannabis myrcene content >0.5%), benzodiazepines, barbiturates, alcohol, and other CNS depressants, necessitating caution in concurrent use and avoidance of driving or operating machinery after consumption. No formal drug-drug interaction studies in humans have been conducted; theoretical CYP450-mediated metabolic interactions are plausible given monoterpene enzyme-modulating properties, but data are insufficient to specify interaction profiles with pharmaceutical agents. Pregnancy and lactation safety is unestablished; given CNS-active and potentially cytotoxic properties observed in vitro, use during pregnancy or breastfeeding is not recommended without medical supervision; individuals with sedative medication regimens, hepatic impairment, or known monoterpene hypersensitivity should exercise caution.